Antibodies against recombinant enzyme in the treatment of Fabry disease: Now you see them, now you don't

Sanne Jolien van der Veen; Mirjam Langeveld

doi:https://doi.org/10.1016/j.omtm.2022.10.007

Antibodies against recombinant enzyme in the treatment of Fabry disease: Now you see them, now you don't

Sanne Jolien van der Veen, Mirjam Langeveld

Research output: Contribution to journal › Comment/Letter to the editor › Academic

1 Citation (Scopus)

Original language	English
Pages (from-to)	324-326
Number of pages	3
Journal	Molecular Therapy - Methods and Clinical Development
Volume	27
DOIs	https://doi.org/10.1016/j.omtm.2022.10.007
Publication status	Published - 8 Dec 2022

Access to Document

https://doi.org/10.1016/j.omtm.2022.10.007

Cite this

@article{9a804fc4b6ae40079f125fff9cf7087a,

title = "Antibodies against recombinant enzyme in the treatment of Fabry disease: Now you see them, now you don't",

author = "{van der Veen}, {Sanne Jolien} and Mirjam Langeveld",

note = "Funding Information: M.L. is involved in pre-marketing studies with Genzyme, Protalix, and Idorsia. S.J.vdV. was involved in a pre-marketing study with Protalix. All financial arrangements are made through AMC Research BV. No fees, travel support, or grants have been obtained (directly or indirectly) from the pharmaceutical industry.",

year = "2022",

month = dec,

day = "8",

doi = "https://doi.org/10.1016/j.omtm.2022.10.007",

language = "English",

volume = "27",

pages = "324--326",

journal = "Molecular Therapy - Methods and Clinical Development",

issn = "2329-0501",

publisher = "Cell Press",

}

TY - JOUR

T1 - Antibodies against recombinant enzyme in the treatment of Fabry disease

T2 - Now you see them, now you don't

AU - van der Veen, Sanne Jolien

AU - Langeveld, Mirjam

N1 - Funding Information: M.L. is involved in pre-marketing studies with Genzyme, Protalix, and Idorsia. S.J.vdV. was involved in a pre-marketing study with Protalix. All financial arrangements are made through AMC Research BV. No fees, travel support, or grants have been obtained (directly or indirectly) from the pharmaceutical industry.

PY - 2022/12/8

Y1 - 2022/12/8

UR - http://www.scopus.com/inward/record.url?scp=85140923493&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.omtm.2022.10.007

DO - https://doi.org/10.1016/j.omtm.2022.10.007

M3 - Comment/Letter to the editor

C2 - 36381299

SN - 2329-0501

VL - 27

SP - 324

EP - 326

JO - Molecular Therapy - Methods and Clinical Development

JF - Molecular Therapy - Methods and Clinical Development

ER -

Antibodies against recombinant enzyme in the treatment of Fabry disease: Now you see them, now you don't

Access to Document

Other files and links

Cite this